# RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II Trial

> **NCT03067493** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 98 (estimated)

## Conditions studied

- Primary Liver Cancer
- Radiofrequency Ablation
- Immunotherapy
- Hepatectomy

## Interventions

- **BIOLOGICAL:** Neo-MASCT

## Key facts

- **NCT ID:** NCT03067493
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-25
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2022-01-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03067493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03067493, "RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03067493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*